UNSPSC 51152050: Baclofen hydrochloride

This classification denotes a muscle relaxant with the molecular formula C10H12CLNO2.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64OSE3996V. Most nations, for tariff and trade purposes, schedule baclofen hydrochloride under HS 29224995. As of Q4 2014, BACLOFEN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Baclofen hydrochloride bears US NLM identifiers UMLS ID C2983921 and NCI Concept Code C90887. SMILES: C1CC(CCC1C(CC(=O)O)CN)CL.CL.

UNSPSC 51152050 Baclofen hydrochloride is a Commodity code identifying a specific pharmaceutical product used in muscle relaxation and spasticity management; however, recent state and local procurement activity under this code shows minimal direct alignment with the nominal scope. State and local health agencies and counties do procure pharmaceuticals and medical supplies through competitive bidding, but the single recent opportunity in the dataset—Seminole County, Florida's IFB for naloxone and drug deactivation systems—addresses opioid overdose response and harm reduction, not baclofen treatment. Issuing bodies soliciting under pharmaceutical and medical-supply codes span county health departments, municipal public-health agencies, and special-purpose health districts, typically through IFB or RFQ vehicles with fixed-fee pricing and standard insurance, E-Verify, and drug-free workplace compliance requirements.

The available data offers limited geographic or frequency signals for baclofen procurement specifically. Seminole County's naloxone IFB60459723LAS, posted June 30, 2026, with response due July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building in Sanford, Florida. The procurement included standard state and local requirements—electronic bidding, workers' compensation and general liability insurance, E-Verify verification, and a three-month probationary termination clause—and noted potential FEMA funding with associated federal compliance obligations. The mismatch between the code's nominal pharmaceutical scope and the recent activity suggests either sparse baclofen-specific procurement in the state and local space or mis-tagging in the underlying opportunity record. Professionals pursuing this code should verify the actual frequency and jurisdiction mix of baclofen or muscle-relaxant pharmaceutical procurement through supplemental market research rather than relying on the single available reference.